Newest OncoKB updates: November 13, 2023

[Contact OncoKB]

Dear OncoKB user,

Here are the latest OncoKB updates:

November 13, 2023 Data version: v4.11

Updated therapeutic implications - Changed level of evidence

Gene	Mutation	Cancer Type	Drug(s)	Previous Level	Current Level	Reason
IDH1	R132	Myelodysplastic Syndromes	Ivosidenib	3B	1	FDA-approval of Ivosidenib for patients with IDH1-mutant myelodysplastic syndrome; Abstract: DiNardo et al. Abstract# MDS-457, SOHO 2023

Updated therapeutic implications - Addition of therapies for variants with a level of evidence

• 
  

Gene	Mutation	Cancer Type	Current Level of Evidence	Drug(s) currently in OncoKB™	Drug(s) added to OncoKB™	Evidence
BRCA1	Oncogenic Mutations	Prostate Cancer	1	Olaparib, Rucaparib, Olaparib + Abiraterone + Prednisone, Talazoparib + Enzalutamide (Level 1)	Niraparib + Abiraterone Acetate + Prednisone (Level 1)	FDA-approval of Niraparib + Abiraterone Acetate + Prednisone; PMID: 36952634
BRCA2

• Addition of 4 new genes:
  

• CTNNA1   FGF10   FGF14   HSP90AA1

As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you.

--

The OncoKB Team